HUTCHMED China vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

HUTCHMED China Ltd (0013.HK)

Q3 202625 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

July 202625 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

Latest25 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.